JO
PLX icon

John Overdeck’s Protalix BioTherapeutics PLX Stock Holding History

John Overdeck’s Portfolio PLX Stock Details PLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$99.1K Buy
42,515
+24,386
+135% +$51.6K ﹤0.01% 4889
2026
Q1 		$39.3K Buy
+18,129
New +$45K ﹤0.01% 4473
2025
Q3 		– Sell
-71,537
Closed -$106K – 3859
2025
Q2 		$106K Sell
71,537
-14,817
-17% -$30.3K ﹤0.01% 2990
2025
Q1 		$221K Buy
+86,354
New +$206K ﹤0.01% 2824
2024
Q1 		– Sell
-19,600
Closed -$34.9K – 3298
2023
Q4 		$34.9K Sell
19,600
-27,700
-59% -$43.1K ﹤0.01% 3025
2023
Q3 		$78.5K Sell
47,300
-7,825
-14% -$14K ﹤0.01% 2767
2023
Q2 		$110K Sell
55,125
-138,969
-72% -$331K ﹤0.01% 2743
2023
Q1 		$408K Buy
194,094
+183,968
+1,817% +$323K ﹤0.01% 2294
2022
Q4 		$13.9K Sell
10,126
-225
-2% -$247 ﹤0.01% 2711
2022
Q3 		$11K Sell
10,351
-15,159
-59% -$16.8K ﹤0.01% 2414
2022
Q2 		$28K Buy
+25,510
New +$29.8K ﹤0.01% 2382
2015
Q1 		– Sell
-4,021
Closed -$74K – 2803
2014
Q4 		$74K Buy
4,021
+1,139
+40% +$24.5K ﹤0.01% 2147
2014
Q3 		$70K Sell
2,882
-912
-24% -$26.3K ﹤0.01% 1683
2014
Q2 		$138K Buy
+3,794
New +$153K ﹤0.01% 2027
2014
Q1 		– Sell
-5,357
Closed -$208K – 2199
2013
Q4 		$208K Buy
5,357
+3,487
+186% +$147K ﹤0.01% 2001
2013
Q3 		$85K Sell
1,870
-1,726
-48% -$88.6K ﹤0.01% 1761
2013
Q2 		$177K Buy
+3,596
New +$191K ﹤0.01% 1805

Other funds holding PLX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
SWP
Stratos Wealth Partners Beachwood, Ohio $9.93B AUM 28.91% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

John Overdeck's PLX Position: Q2 2026 in Review

John Overdeck increased its Protalix BioTherapeutics (PLX) stake by 135% in Q2 2026, buying an estimated $51.6K and bringing the position to 42,515 shares worth $99.1K. The position accounts for ﹤0.01% of the portfolio, ranked #4889.

John Overdeck first reported a position in PLX in Q2 2013 and has held it in 17 quarters since. The position peaked at $408K in Q1 2023. 101 funds tracked by Wall St. Rank hold PLX as of Q2 2026.

  • John Overdeck held 42,515 shares of Protalix BioTherapeutics worth $99.1K as of Q2 2026.
  • John Overdeck bought 24,386 Protalix BioTherapeutics shares in Q2 2026, an estimated $51.6K.
  • Protalix BioTherapeutics made up ﹤0.01% of John Overdeck's portfolio in Q2 2026, its #4889 holding.
  • John Overdeck first reported a position in Protalix BioTherapeutics in Q2 2013 and has held it in 17 quarters since.
  • John Overdeck's Protalix BioTherapeutics position peaked at $408K in Q1 2023.
  • 101 funds tracked by Wall St. Rank held Protalix BioTherapeutics as of Q2 2026.

Based on Two Sigma Investments's 13F filing for Q2 2026, filed 14 Aug 2026.